FCB Health Network chief commercial officer Michael Guarino announced the launch of Solve(d), a new offering that enhances the evidence-based planning and execution of clients’ healthcare marketing strategies and tactics.
Johnson & Johnson Vision, a broad-based global leader in eye health, launched a worldwide campaign to #spotlightsight in honor of World Sight Day on October 11, 2018.
Fingerpaint opened an office in Morristown, N.J., heading by Mark Willmann. The healthcare agency’s first office in New Jersey joins other locations in New York, Pennsylvania, Arizona, and Ohio.
The U.S. FDA accepted Novartis’ New Drug Application for the investigational oral, once-daily siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis in adults.
Evoke Acquires Navience Healthcare Solutions, LLC Adds Depth and Breadth in High-Growth Market Access & Payer Marketing Sector NEW YORK, Sept. 27, 2018 /PRNewswire/ — Evoke (www.evokegroup.com), part of Huntsworth plc (HNT: LSE), today announces the acquisition of New Jersey-based Navience Healthcare Solutions. Navience is a full-service market access and payer marketing agency […]
TrialScope, the global leader in clinical trial transparency and compliance solutions, announced the launch of the company’s Clinical Trial Transparency Service (CTTS).
Angelina Sciolla joined Benchworks as Executive Creative Director to lead the company’s creative team and help build on the agency’s creative offerings.
FCB Health Continues Global Expansion with New Frankfurt Office and Network Ambassadors Stationed in Amsterdam and Zurich
FCB Health Europe President Joerg Hempelmann announced the launch of FCB Health Frankfurt, along with Network ambassadors stationed in Amsterdam and Zurich.
St. Louis-based 2e Group announced the acquisition of Fire & Rain, an independent field force training, leadership development, and meetings and events consultancy located in Evansville, Indiana.
Healthline Media Inc. announced that the company’s Healthline property, with a total of 67.3 million unique visitors in August 2018, is one of the top 50 digital media properties for the first time according to media measurement firm, comScore.
Lilly Announces Initiation of IXORA-R Head-to-Head Trial Comparing Taltz and Tremfya in Patients with Moderate-to-Severe Plaque Psoriasis
Eli Lilly and Company announced today the initiation of the IXORA-R head-to-head clinical trial, designed to evaluate superiority between Taltz (ixekizumab) and Tremfya (guselkumab) in adult patients with moderate-to-severe plaque psoriasis.
Amgen and AstraZeneca announced that the U.S. FDA granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma without an eosinophilic phenotype.
Boston Scientific announced a definitive agreement to acquire Augmenix Inc., a privately held company that has developed and commercialized the SpaceOAR System, a therapy used to reduce common and debilitating side effects that men may experience after receiving prostate cancer radiotherapy.
Anne White was promoted to senior vice president of Eli Lilly and Company and president of Lilly Oncology effective September 1, 2018.
Americans Experiencing A Vacation Deficit Are More Likely To Show Signs Of Moderate To Severe Depression
Americans suffering from a “vacation deficit” are nearly two times as likely to show signs of moderately severe to severe depression compared to the national average, according to the 10th annual Allianz Global Assistance Vacation Confidence Index.
The Janssen Pharmaceutical Companies of J&J announced the U.S. FDA approval of Imbruvica (ibrutinib) in combination with rituximab for the treatment of Waldenström’s macroglobulinemia.
The U.S. FDA approved Ortho Dermatologics’ NDA for Altreno (tretinoin 0.05%) lotion, indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.
Sierra Oncology Inc. announced that the clinical-stage drug-development company acquired the drug candidate momelotinib from Gilead Sciences.
TrialAssure Partners with Otsuka Pharmaceutical to Provide Clinical Trial Disclosure Reporting System for Global Pipeline
TrialAssure will partner with Otsuka Pharmaceutical Development and Commercialization Inc. to implement its comprehensive transparency management system for all compounds in Otsuka’s drug development pipeline.